● neutral
Impact
PhasePhase 1b
Time to marketAt least 3-5 years away, if ever. The drug is still in Phase 1b testing. Even under a Fast Track pathway, it would need to complete Phase 2 and Phase 3 trials before any approval filing.
PLN-101095 Updated Nov 13
What to watch
PLN-101095 is an early-stage oncology asset at a cash-strapped company that already lost its lead pipeline drug. Watch for FORTIFY enrollment completion updates and any efficacy signals from the Phase 1b expansion cohorts. The stock is trading near cash value, so positive data could drive a meaningful rally, but the company's financial runway and lack of analyst coverage are serious headwinds. No near-term binary catalyst is on the calendar.
Bull case
- Novel mechanism: PLN-101095 is a first-in-class oral dual inhibitor of alpha-v-beta-8 and alpha-v-beta-1 integrins, targeting a key immune-suppression pathway that may re-sensitize checkpoint-refractory tumors. No approved drug targets this mechanism.
- FDA Fast Track designation (August 2026) provides regulatory benefits including rolling NDA review and priority review eligibility, signaling FDA interest in the program.
- FORTIFY Phase 1b trial is actively enrolling with strong enrollment per the company's November 2026 update, suggesting investigator and patient interest.
Bear case
- Very early stage: PLN-101095 is only in Phase 1b testing with no efficacy data from controlled trials yet. Most oncology drugs fail in Phase 2 or 3.
- Company is financially distressed: Pliant cut 45% of its workforce in May 2025 after terminating its lead asset bexotegrast (IPF) due to safety issues. Q3 2026 net loss was $24.38M with limited cash runway.
- Institutional exodus: Major holders JPMorgan (-84%), UBS (-82%), Invesco (-79%), and Morgan Stanley (-51%) all significantly trimmed or nearly exited their positions in Q3 2026.